APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.

Related Keywords

Ohio ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,Americans ,American ,Daiichi Sankyo ,Pamelab Morris ,Stevene Nissen ,Vera Bittner ,Eli Lilly ,Amgen ,University Of Alabama At Birmingham ,Novartis ,Pfizer ,University Of Cambridge ,Sanofi Aventis ,Astrazeneca ,University Of South Carolina ,European Society Of Cardiology ,Bristol Myers Squibb ,Gilead Sciences ,Medicines Company ,American College Of Cardiology ,Krka Pharmaceuticals ,Journal Of The American Medical Association ,European Atherosclerosis Society ,Medtronic ,Novo Nordisk ,Silence Therapeutics ,Cleveland Clinic ,American College ,American Medical ,Medscape Cardiology ,Medical University ,South Carolina ,Brian Ference ,Esperion Therapeutics ,Civi Biopharma ,European Society ,European Atherosclerosis ,Presented April ,Cv ,Ardiovascular ,Aortic Stenosis ,Valvar Aortic Stenosis , ,Clinical Research ,Clinical Trials ,Linical Studies ,Congenital Heart Disease ,Cardiovascular Disease ,Vd Cardiovascular Disease ,Low Ldl Cholesterol ,Ypobetalipoproteinemia ,Ow Low Density Lipoprotein Cholesterol ,Lipids ,Ipid Management ,Adhd ,Attention Deficit Hyperactivity Disorder ,Ttention Deficit Hyperactivity Disorder Adhd ,Path ,